Payload Information
General Information of This Payload
| Payload ID | PAY0AFEPS |
|||||
|---|---|---|---|---|---|---|
| Name | DGN462 |
|||||
| Synonyms |
DGN462; 1394079-41-4; SCHEMBL12523030; DGN 462; AKOS040732962; HY-101150; CS-0020917
Click to Show/Hide
|
|||||
| Target(s) | Human Deoxyribonucleic acid (hDNA) | |||||
| Structure |
|
|||||
| Formula | C53H59N5O9S |
|||||
| Isosmiles | [H]SC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])N(c1c([H])c(C([H])([H])Oc2c([H])c3c(c([H])c2OC([H])([H])[H])C(=O)N2c4c([H])c([H])c([H])c([H])c4C([H])([H])[C@@]2([H])C([H])=N3)c([H])c(C([H])([H])Oc2c([H])c3c(c([H])c2OC([H])([H])[H])C(=O)N2c4c([H])c([H])c([H])c([H])c4C([H])([H])[C@@]2([H])C([H])([H])N3[H])c1[H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])[H] |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C53H59N5O9S/c1-53(2,68)33-56(14-15-64-18-19-65-17-16-61-3)38-21-34(31-66-49-27-43-41(25-47(49)62-4)51(59)57-39(29-54-43)23-36-10-6-8-12-45(36)57)20-35(22-38)32-67-50-28-44-42(26-48(50)63-5)52(60)58-40(30-55-44)24-37-11-7-9-13-46(37)58/h6-13,20-22,25-29,39-40,55,68H,14-19,23-24,30-33H2,1-5H3/t39-,40-/m0/s1
|
|||||
| InChIKey |
DOKWDOLZCMETIJ-ZAQUEYBZSA-N
|
|||||
| IUPAC Name |
(12aS)-9-[[3-[[(12aS)-8-methoxy-6-oxo-11,12,12a,13-tetrahydroindolo[2,1-c][1,4]benzodiazepin-9-yl]oxymethyl]-5-[2-[2-(2-methoxyethoxy)ethoxy]ethyl-(2-methyl-2-sulfanylpropyl)amino]phenyl]methoxy]-8-methoxy-12a,13-dihydroindolo[2,1-c][1,4]benzodiazepin-6-one
|
|||||
| Pharmaceutical Properties | Molecule Weight |
942.148 |
Polar area |
132.86 |
||
Complexity |
941.4033495 |
xlogp Value |
8.3406 |
|||
Heavy Count |
68 |
Rot Bonds |
26 |
|||
Hbond acc |
13 |
Hbond Donor |
2 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
IMGN-779 [Phase 1 (Terminated)]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 15) | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
EOL-1 tumor-bearing mice received a single intravenous bolus administration of vehicle, IMGN779, or Ab-DGN462, with each conjugate molecule dosed at approximately 1.5 mg/kg ADC by antibody concentration (i.e., 10 or 30 ug/kg linked IGN).
|
||||
| In Vivo Model | EOL-1 CDX model | ||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 30) | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
IMGN779 (0.5 mg/kg, a single dose) induces efficient tumor cell killing in cell line-derived models of MV4-11 cells with CD33 expression with high expression.
|
||||
| In Vivo Model | MV4-11 CDX model | ||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
References